| Dr Erika Cajsa Schumacher, MD | |
|
116 Narrow Gauge Sq Ste 101, Farmington, ME 04938-5880 | |
| (207) 956-0980 | |
| (207) 956-0981 |
| Full Name | Dr Erika Cajsa Schumacher |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 116 Narrow Gauge Sq Ste 101, Farmington, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396902086 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD20332 (Maine) | Primary |
| Entity Name | Franklin Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558305847 PECOS PAC ID: 4385615145 Enrollment ID: O20090805000364 |
News Archive
Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
Researchers at North Carolina State University have discovered that the good bacteria found in dairy products and linked to positive health benefits in the human body might also be an effective vehicle for an oral vaccine that can provide immunity to anthrax exposure.
Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.
Warnings are being issued concerning the drug Tamiflu by both the drug company Roche and the Food and Drug Administration (FDA) in the U.S.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erika Cajsa Schumacher, MD 116 Narrow Gauge Sq Ste 101, Farmington, ME 04938-5880 Ph: (207) 956-0980 | Dr Erika Cajsa Schumacher, MD 116 Narrow Gauge Sq Ste 101, Farmington, ME 04938-5880 Ph: (207) 956-0980 |
News Archive
Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
Researchers at North Carolina State University have discovered that the good bacteria found in dairy products and linked to positive health benefits in the human body might also be an effective vehicle for an oral vaccine that can provide immunity to anthrax exposure.
Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.
Warnings are being issued concerning the drug Tamiflu by both the drug company Roche and the Food and Drug Administration (FDA) in the U.S.
› Verified 6 days ago
Ryan Joseph Whitt, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 181 Franklin Health Commons, Farmington, ME 04938 Phone: 207-778-0482 Fax: 207-778-0133 | |
Iris Silverstein, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 131 Franklin Health Cmns, Franklin Hlth Child & Adol. Developmental Pediatrics, Farmington, ME 04938 Phone: 207-779-6623 Fax: 207-779-2323 | |
Tanya Lever, MSN,PNP-PC Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 181 Franklin Health Commons, Farmington, ME 04938 Phone: 207-778-0482 | |
Gabriel Civiello, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 181 Franklin Health Commons, Farmington, ME 04938 Phone: 207-778-0482 Fax: 207-778-0133 | |
Heather Kay Lynn, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 181 Franklin Health Commons, Farmington, ME 04938 Phone: 207-778-0482 Fax: 207-778-0133 |